speb/financial-data huggingface dataset:
APO cash_flow (annual, 2024-12-31) — Change In Other Current Liabilities: -1969000000.00
APO cash_flow (annual, 2024-12-31) — Change In Other Working Capital: 4105000000.00
APO cash_flow (annual, 2024-12-31) — Change In Working Capital: 2136000000.00
APO cash_flow (annual, 2024-12-31) — Changes In Cash: -576000000.00
APO balance_sheet (annual, 2024-12-31) — Common Stock: 0.00
APO cash_flow (annual, 2024-12-31) — Common Stock Dividend Paid: -1092000000.00
APO balance_sheet (annual, 2024-12-31) — Common Stock Equity: 15855000000.00
APO cash_flow (annual, 2024-12-31) — Common Stock Payments: -890000000.00
APO income_statement (annual, 2024-12-31) — Cost Of Revenue: 1140000000.00
APO balance_sheet (annual, 2024-12-31) — Current Assets: 215704000000.00
APO balance_sheet (annual, 2024-12-31) — Current Deferred Liabilities: 253637000000.00
APO balance_sheet (annual, 2024-12-31) — Current Deferred Revenue: 253637000000.00
APO balance_sheet (annual, 2024-12-31) — Current Liabilities: 269615000000.00
APO cash_flow (annual, 2024-12-31) — Depreciation Amortization Depletion: 1075000000.00
APO cash_flow (annual, 2024-12-31) — Depreciation And Amortization: 1075000000.00
APO income_statement (annual, 2024-12-31) — Diluted Average Shares: 604000000.00
APO income_statement (quarterly, 2024-12-31) — Diluted Average Shares: 603000000.00
APO income_statement (annual, 2024-12-31) — Diluted EPS: 7.33
APO income_statement (quarterly, 2024-12-31) — Diluted EPS: 2.39
APO income_statement (annual, 2024-12-31) — Diluted NI Availto Com Stockholders: 3394000000.00
APO balance_sheet (annual, 2024-12-31) — Duefrom Related Parties Current: 584000000.00
APO balance_sheet (annual, 2024-12-31) — Dueto Related Parties Current: 710000000.00
APO income_statement (annual, 2024-12-31) — EBIT: 7774000000.00
APO income_statement (annual, 2024-12-31) — EBITDA: 8849000000.00
APO cash_flow (annual, 2024-12-31) — Effect Of Exchange Rate Changes: -3000000.00
APO cash_flow (annual, 2024-12-31) — End Cash Position: 17112000000.00
APO balance_sheet (annual, 2024-12-31) — Financial Assets: 8154000000.00
APO cash_flow (annual, 2024-12-31) — Financing Cash Flow: 57972000000.00
APO cash_flow (annual, 2024-12-31) — Free Cash Flow: 3253000000.00
APO cash_flow (annual, 2024-12-31) — Gain Loss On Investment Securities: -4885000000.00
APO income_statement (annual, 2024-12-31) — Gain On Sale Of Security: 97000000.00
APO balance_sheet (annual, 2024-12-31) — Gains Losses Not Affecting Retained Earnings: -5494000000.00
APO income_statement (annual, 2024-12-31) — General And Administrative Expense: 2638000000.00
APO balance_sheet (annual, 2024-12-31) — Goodwill: 4327000000.00
APO balance_sheet (annual, 2024-12-31) — Goodwill And Other Intangible Assets: 4327000000.00
APO income_statement (annual, 2024-12-31) — Gross Profit: 24974000000.00
APO cash_flow (annual, 2024-12-31) — Income Tax Paid Supplemental Data: 1048000000.00
APO cash_flow (quarterly, 2024-12-31) — Income Tax Paid Supplemental Data: 409000000.00
APO income_statement (annual, 2024-12-31) — Interest Expense: 339000000.00
APO income_statement (annual, 2024-12-31) — Interest Expense Non Operating: 339000000.00
APO income_statement (annual, 2024-12-31) — Interest Income: 172000000.00
APO income_statement (annual, 2024-12-31) — Interest Income Non Operating: 172000000.00
APO cash_flow (annual, 2024-12-31) — Interest Paid Supplemental Data: 805000000.00
APO balance_sheet (annual, 2024-12-31) — Invested Capital: 26443000000.00
APO cash_flow (annual, 2024-12-31) — Investing Cash Flow: -61801000000.00
APO balance_sheet (annual, 2024-12-31) — Investmentin Financial Assets: 1524000000.00
APO balance_sheet (annual, 2024-12-31) — Investments And Advances: 125515000000.00
APO cash_flow (annual, 2024-12-31) — Issuance Of Capital Stock: 0.00
APO cash_flow (quarterly, 2024-12-31) — Issuance Of Capital Stock: 0.00
APO cash_flow (annual, 2024-12-31) — Issuance Of Debt: 7945000000.00
APO balance_sheet (annual, 2024-12-31) — Line Of Credit: 0.00
APO balance_sheet (quarterly, 2024-12-31) — Line Of Credit: 0.00
APO balance_sheet (annual, 2024-12-31) — Long Term Debt: 10588000000.00
APO balance_sheet (annual, 2024-12-31) — Long Term Debt And Capital Lease Obligation: 10588000000.00
APO cash_flow (annual, 2024-12-31) — Long Term Debt Issuance: 7945000000.00
APO cash_flow (annual, 2024-12-31) — Long Term Debt Payments: -5259000000.00
APO balance_sheet (annual, 2024-12-31) — Long Term Equity Investment: 1082000000.00
APO balance_sheet (annual, 2024-12-31) — Long Term Provisions: 49902000000.00
APO balance_sheet (quarterly, 2024-12-31) — Long Term Provisions: 49902000000.00
APO balance_sheet (annual, 2024-12-31) — Minority Interest: 13727000000.00
APO income_statement (annual, 2024-12-31) — Minority Interests: -1796000000.00
APO cash_flow (annual, 2024-12-31) — Net Business Purchase And Sale: 55591000000.00
APO cash_flow (annual, 2024-12-31) — Net Common Stock Issuance: -890000000.00
APO income_statement (annual, 2024-12-31) — Net Income: 4577000000.00
APO income_statement (annual, 2024-12-31) — Net Income Common Stockholders: 3297000000.00
APO income_statement (annual, 2024-12-31) — Net Income Continuous Operations: 6373000000.00
APO income_statement (annual, 2024-12-31) — Net Income From Continuing And Discontinued Operation: 4577000000.00
APO income_statement (annual, 2024-12-31) — Net Income From Continuing Operation Net Minority Interest: 4577000000.00
APO cash_flow (annual, 2024-12-31) — Net Income From Continuing Operations: 6373000000.00
APO income_statement (annual, 2024-12-31) — Net Income Including Noncontrolling Interests: 6373000000.00
APO income_statement (annual, 2024-12-31) — Net Interest Income: -175000000.00
APO cash_flow (annual, 2024-12-31) — Net Investment Purchase And Sale: -116201000000.00
APO cash_flow (annual, 2024-12-31) — Net Issuance Payments Of Debt: 2686000000.00
APO cash_flow (annual, 2024-12-31) — Net Long Term Debt Issuance: 2686000000.00
APO income_statement (annual, 2024-12-31) — Net Non Operating Interest Income Expense: -175000000.00
APO cash_flow (annual, 2024-12-31) — Net Other Financing Charges: 57365000000.00
APO cash_flow (annual, 2024-12-31) — Net Other Investing Changes: -1191000000.00
APO cash_flow (annual, 2024-12-31) — Net Preferred Stock Issuance: 0.00
APO cash_flow (quarterly, 2024-12-31) — Net Preferred Stock Issuance: 0.00
APO balance_sheet (annual, 2024-12-31) — Net Tangible Assets: 12926000000.00
APO balance_sheet (annual, 2024-12-31) — Non Current Deferred Assets: 7173000000.00
APO income_statement (annual, 2024-12-31) — Normalized EBITDA: 9693000000.00
APO income_statement (annual, 2024-12-31) — Normalized Income: 5300308000.00
APO cash_flow (annual, 2024-12-31) — Operating Cash Flow: 3253000000.00
APO cash_flow (annual, 2024-12-31) — Operating Gains Losses: -4885000000.00
APO income_statement (annual, 2024-12-31) — Operating Income: 8299000000.00
APO income_statement (annual, 2024-12-31) — Operating Revenue: 26095000000.00
APO balance_sheet (annual, 2024-12-31) — Ordinary Shares Number: 565738933.00
APO balance_sheet (annual, 2024-12-31) — Other Equity Adjustments: -5494000000.00
APO income_statement (annual, 2024-12-31) — Other Gand A: 1170000000.00
APO income_statement (annual, 2024-12-31) — Other Income Expense: -689000000.00
APO balance_sheet (annual, 2024-12-31) — Other Investments: 122909000000.00
APO cash_flow (annual, 2024-12-31) — Other Non Cash Items: -2167000000.00
APO balance_sheet (annual, 2024-12-31) — Other Non Current Assets: 17022000000.00
APO balance_sheet (annual, 2024-12-31) — Other Non Current Liabilities: 66712000000.00
APO income_statement (annual, 2024-12-31) — Other Non Operating Income Expenses: 155000000.00
APO income_statement (annual, 2024-12-31) — Other Operating Expenses: 14037000000.00
APO balance_sheet (annual, 2024-12-31) — Other Payable: 11652000000.00
APO balance_sheet (annual, 2024-12-31) — Other Receivables: 8194000000.00
APO balance_sheet (annual, 2024-12-31) — Other Short Term Investments: 189814000000.00
APO income_statement (annual, 2024-12-31) — Otherunder Preferred Stock Dividend: 1183000000.00
APO balance_sheet (annual, 2024-12-31) — Payables: 15978000000.00
APO balance_sheet (annual, 2024-12-31) — Payables And Accrued Expenses: 15978000000.00
APO balance_sheet (annual, 2024-12-31) — Preferred Shares Number: 28749765.00
APO balance_sheet (annual, 2024-12-31) — Preferred Stock: 1398000000.00
APO cash_flow (annual, 2024-12-31) — Preferred Stock Dividend Paid: -97000000.00
APO income_statement (annual, 2024-12-31) — Preferred Stock Dividends: 97000000.00
APO balance_sheet (annual, 2024-12-31) — Preferred Stock Equity: 1398000000.00
APO cash_flow (annual, 2024-12-31) — Preferred Stock Issuance: 0.00
APO cash_flow (quarterly, 2024-12-31) — Preferred Stock Issuance: 0.00
APO income_statement (annual, 2024-12-31) — Pretax Income: 7435000000.00
APO cash_flow (annual, 2024-12-31) — Purchase Of Business: -3835000000.00
APO cash_flow (annual, 2024-12-31) — Purchase Of Investment: -116201000000.00
APO balance_sheet (annual, 2024-12-31) — Receivables: 8778000000.00
APO income_statement (annual, 2024-12-31) — Reconciled Cost Of Revenue: 1140000000.00
APO income_statement (annual, 2024-12-31) — Reconciled Depreciation: 1075000000.00
APO cash_flow (annual, 2024-12-31) — Repayment Of Debt: -5259000000.00
APO cash_flow (annual, 2024-12-31) — Repurchase Of Capital Stock: -890000000.00
APO balance_sheet (annual, 2024-12-31) — Restricted Cash: 946000000.00
APO income_statement (annual, 2024-12-31) — Restructuring And Mergern Acquisition: 941000000.00
APO balance_sheet (annual, 2024-12-31) — Retained Earnings: 6022000000.00
APO income_statement (annual, 2024-12-31) — Salaries And Wages: 1468000000.00
APO cash_flow (annual, 2024-12-31) — Sale Of Business: 59426000000.00
APO income_statement (annual, 2024-12-31) — Selling General And Administration: 2638000000.00
APO balance_sheet (annual, 2024-12-31) — Share Issued: 565738933.00
APO income_statement (annual, 2024-12-31) — Special Income Charges: -941000000.00
APO cash_flow (annual, 2024-12-31) — Stock Based Compensation: 721000000.00
APO balance_sheet (annual, 2024-12-31) — Stockholders Equity: 17253000000.00
APO balance_sheet (annual, 2024-12-31) — Tangible Book Value: 11528000000.00
APO income_statement (annual, 2024-12-31) — Tax Effect Of Unusual Items: -120692000.00
APO income_statement (annual, 2024-12-31) — Tax Provision: 1062000000.00
APO income_statement (annual, 2024-12-31) — Tax Rate For Calcs: 0.14
APO balance_sheet (annual, 2024-12-31) — Total Assets: 377895000000.00
APO balance_sheet (annual, 2024-12-31) — Total Capitalization: 27841000000.00
APO balance_sheet (annual, 2024-12-31) — Total Debt: 10588000000.00
APO balance_sheet (annual, 2024-12-31) — Total Equity Gross Minority Interest: 30980000000.00
APO income_statement (annual, 2024-12-31) — Total Expenses: 17815000000.00
APO balance_sheet (annual, 2024-12-31) — Total Liabilities Net Minority Interest: 346915000000.00
APO balance_sheet (annual, 2024-12-31) — Total Non Current Assets: 162191000000.00
APO balance_sheet (annual, 2024-12-31) — Total Non Current Liabilities Net Minority Interest: 77300000000.00
APO income_statement (annual, 2024-12-31) — Total Other Finance Cost: 8000000.00
APO income_statement (annual, 2024-12-31) — Total Unusual Items: -844000000.00
APO income_statement (annual, 2024-12-31) — Total Unusual Items Excluding Goodwill: -844000000.00
APO balance_sheet (annual, 2024-12-31) — Working Capital: -53911000000.00
APO income_statement (quarterly, 2025-03-31) — +Operating Expense: 3697000000.00
APO income_statement (quarterly, 2025-03-31) — +Total Revenue: 5556000000.00
APO balance_sheet (quarterly, 2025-03-31) — Accounts Payable: 3773000000.00
APO balance_sheet (quarterly, 2025-03-31) — Additional Paid In Capital: 15527000000.00
APO balance_sheet (quarterly, 2025-03-31) — Available For Sale Securities: 1299000000.00
APO income_statement (quarterly, 2025-03-31) — Average Dilution Earnings: 0.00
APO income_statement (quarterly, 2025-03-31) — Basic Average Shares: 587258883.00
APO income_statement (quarterly, 2025-03-31) — Basic EPS: 0.68
APO cash_flow (quarterly, 2025-03-31) — Beginning Cash Position: 17112000000.00
APO balance_sheet (quarterly, 2025-03-31) — Capital Stock: 1398000000.00
APO balance_sheet (quarterly, 2025-03-31) — Cash And Cash Equivalents: 13300000000.00
APO balance_sheet (quarterly, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 216431000000.00
APO cash_flow (quarterly, 2025-03-31) — Cash Dividends Paid: -302000000.00
APO cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Financing Activities: 14274000000.00
APO cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Investing Activities: -16888000000.00
APO cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Operating Activities: 1012000000.00
APO cash_flow (quarterly, 2025-03-31) — Change In Other Current Liabilities: -289000000.00
APO cash_flow (quarterly, 2025-03-31) — Change In Other Working Capital: -70000000.00
APO cash_flow (quarterly, 2025-03-31) — Change In Working Capital: -359000000.00
APO cash_flow (quarterly, 2025-03-31) — Changes In Cash: -1602000000.00
APO balance_sheet (quarterly, 2025-03-31) — Common Stock: 0.00
APO cash_flow (quarterly, 2025-03-31) — Common Stock Dividend Paid: -278000000.00
APO balance_sheet (quarterly, 2025-03-31) — Common Stock Equity: 16578000000.00
APO cash_flow (quarterly, 2025-03-31) — Common Stock Payments: -193000000.00
APO income_statement (quarterly, 2025-03-31) — Cost Of Revenue: 326000000.00
APO balance_sheet (quarterly, 2025-03-31) — Current Assets: 228068000000.00
APO balance_sheet (quarterly, 2025-03-31) — Current Deferred Liabilities: 273439000000.00
APO balance_sheet (quarterly, 2025-03-31) — Current Deferred Revenue: 273439000000.00
APO balance_sheet (quarterly, 2025-03-31) — Current Liabilities: 285173000000.00
APO cash_flow (quarterly, 2025-03-31) — Depreciation Amortization Depletion: 308000000.00
APO cash_flow (quarterly, 2025-03-31) — Depreciation And Amortization: 308000000.00
APO income_statement (quarterly, 2025-03-31) — Diluted Average Shares: 592984841.00
APO income_statement (quarterly, 2025-03-31) — Diluted EPS: 0.68
APO income_statement (quarterly, 2025-03-31) — Diluted NI Availto Com Stockholders: 137000000.00
APO balance_sheet (quarterly, 2025-03-31) — Duefrom Related Parties Current: 634000000.00
APO balance_sheet (quarterly, 2025-03-31) — Dueto Related Parties Current: 708000000.00
APO income_statement (quarterly, 2025-03-31) — EBIT: 1262000000.00
APO income_statement (quarterly, 2025-03-31) — EBITDA: 1570000000.00
APO cash_flow (quarterly, 2025-03-31) — Effect Of Exchange Rate Changes: 3000000.00
APO cash_flow (quarterly, 2025-03-31) — End Cash Position: 15513000000.00
APO balance_sheet (quarterly, 2025-03-31) — Financial Assets: 6153000000.00
APO cash_flow (quarterly, 2025-03-31) — Financing Cash Flow: 14274000000.00
APO cash_flow (quarterly, 2025-03-31) — Free Cash Flow: 1012000000.00
APO cash_flow (quarterly, 2025-03-31) — Gain Loss On Investment Securities: -64000000.00
APO income_statement (quarterly, 2025-03-31) — Gain On Sale Of Security: 180000000.00
APO balance_sheet (quarterly, 2025-03-31) — Gains Losses Not Affecting Retained Earnings: -4583000000.00
APO income_statement (quarterly, 2025-03-31) — General And Administrative Expense: 727000000.00
APO balance_sheet (quarterly, 2025-03-31) — Goodwill: 4331000000.00
APO balance_sheet (quarterly, 2025-03-31) — Goodwill And Other Intangible Assets: 4331000000.00
APO income_statement (quarterly, 2025-03-31) — Gross Profit: 5230000000.00
APO cash_flow (quarterly, 2025-03-31) — Income Tax Paid Supplemental Data: 310000000.00
APO income_statement (quarterly, 2025-03-31) — Interest Expense: 81000000.00
APO income_statement (quarterly, 2025-03-31) — Interest Expense Non Operating: 81000000.00
APO income_statement (quarterly, 2025-03-31) — Interest Income: 34000000.00
APO income_statement (quarterly, 2025-03-31) — Interest Income Non Operating: 34000000.00
APO cash_flow (quarterly, 2025-03-31) — Interest Paid Supplemental Data: 321000000.00
APO balance_sheet (quarterly, 2025-03-31) — Invested Capital: 27159000000.00
APO cash_flow (quarterly, 2025-03-31) — Investing Cash Flow: -16888000000.00
APO balance_sheet (quarterly, 2025-03-31) — Investmentin Financial Assets: 1299000000.00
APO balance_sheet (quarterly, 2025-03-31) — Investments And Advances: 131990000000.00
APO cash_flow (quarterly, 2025-03-31) — Issuance Of Debt: 294000000.00
APO balance_sheet (quarterly, 2025-03-31) — Long Term Debt: 10581000000.00
APO balance_sheet (quarterly, 2025-03-31) — Long Term Debt And Capital Lease Obligation: 10581000000.00
APO cash_flow (quarterly, 2025-03-31) — Long Term Debt Issuance: 294000000.00
APO cash_flow (quarterly, 2025-03-31) — Long Term Debt Payments: -818000000.00
APO balance_sheet (quarterly, 2025-03-31) — Long Term Equity Investment: 1127000000.00
APO balance_sheet (quarterly, 2025-03-31) — Long Term Provisions: 49897000000.00
APO balance_sheet (quarterly, 2025-03-31) — Minority Interest: 14368000000.00
APO income_statement (quarterly, 2025-03-31) — Minority Interests: -496000000.00
APO cash_flow (quarterly, 2025-03-31) — Net Business Purchase And Sale: 17640000000.00
APO cash_flow (quarterly, 2025-03-31) — Net Common Stock Issuance: -193000000.00
APO income_statement (quarterly, 2025-03-31) — Net Income: 442000000.00
APO income_statement (quarterly, 2025-03-31) — Net Income Common Stockholders: 137000000.00
APO income_statement (quarterly, 2025-03-31) — Net Income Continuous Operations: 938000000.00
APO income_statement (quarterly, 2025-03-31) — Net Income From Continuing And Discontinued Operation: 442000000.00
APO income_statement (quarterly, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: 442000000.00
APO cash_flow (quarterly, 2025-03-31) — Net Income From Continuing Operations: 938000000.00
APO income_statement (quarterly, 2025-03-31) — Net Income Including Noncontrolling Interests: 938000000.00
APO income_statement (quarterly, 2025-03-31) — Net Interest Income: -47000000.00
APO cash_flow (quarterly, 2025-03-31) — Net Investment Purchase And Sale: -35430000000.00
APO cash_flow (quarterly, 2025-03-31) — Net Issuance Payments Of Debt: -524000000.00
APO cash_flow (quarterly, 2025-03-31) — Net Long Term Debt Issuance: -524000000.00
APO income_statement (quarterly, 2025-03-31) — Net Non Operating Interest Income Expense: -47000000.00
APO cash_flow (quarterly, 2025-03-31) — Net Other Financing Charges: 15293000000.00
APO cash_flow (quarterly, 2025-03-31) — Net Other Investing Changes: 902000000.00
APO balance_sheet (quarterly, 2025-03-31) — Net Tangible Assets: 13645000000.00
APO balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Assets: 7606000000.00
APO income_statement (quarterly, 2025-03-31) — Normalized EBITDA: 1657000000.00
APO income_statement (quarterly, 2025-03-31) — Normalized Income: 511078000.00
APO cash_flow (quarterly, 2025-03-31) — Operating Cash Flow: 1012000000.00
APO cash_flow (quarterly, 2025-03-31) — Operating Gains Losses: -64000000.00
APO income_statement (quarterly, 2025-03-31) — Operating Income: 1533000000.00
APO income_statement (quarterly, 2025-03-31) — Operating Revenue: 5551000000.00
APO balance_sheet (quarterly, 2025-03-31) — Ordinary Shares Number: 570432275.00
APO balance_sheet (quarterly, 2025-03-31) — Other Equity Adjustments: -4583000000.00
APO income_statement (quarterly, 2025-03-31) — Other Gand A: 308000000.00
APO income_statement (quarterly, 2025-03-31) — Other Income Expense: -305000000.00
APO balance_sheet (quarterly, 2025-03-31) — Other Investments: 129564000000.00
APO cash_flow (quarterly, 2025-03-31) — Other Non Cash Items: 40000000.00
APO balance_sheet (quarterly, 2025-03-31) — Other Non Current Assets: 16897000000.00
APO balance_sheet (quarterly, 2025-03-31) — Other Non Current Liabilities: 66947000000.00
APO income_statement (quarterly, 2025-03-31) — Other Non Operating Income Expenses: -218000000.00
APO income_statement (quarterly, 2025-03-31) — Other Operating Expenses: 2962000000.00
APO balance_sheet (quarterly, 2025-03-31) — Other Payable: 7253000000.00
APO balance_sheet (quarterly, 2025-03-31) — Other Receivables: 8790000000.00
APO balance_sheet (quarterly, 2025-03-31) — Other Short Term Investments: 203131000000.00
APO income_statement (quarterly, 2025-03-31) — Otherunder Preferred Stock Dividend: 281000000.00
APO balance_sheet (quarterly, 2025-03-31) — Payables: 11734000000.00
APO balance_sheet (quarterly, 2025-03-31) — Payables And Accrued Expenses: 11734000000.00
APO balance_sheet (quarterly, 2025-03-31) — Preferred Shares Number: 28749765.00
APO balance_sheet (quarterly, 2025-03-31) — Preferred Stock: 1398000000.00
APO cash_flow (quarterly, 2025-03-31) — Preferred Stock Dividend Paid: -24000000.00
APO income_statement (quarterly, 2025-03-31) — Preferred Stock Dividends: 24000000.00
APO balance_sheet (quarterly, 2025-03-31) — Preferred Stock Equity: 1398000000.00
APO income_statement (quarterly, 2025-03-31) — Pretax Income: 1181000000.00
APO income_statement (quarterly, 2025-03-31) — Provision For Doubtful Accounts: 8000000.00
APO cash_flow (quarterly, 2025-03-31) — Purchase Of Business: -1336000000.00
APO cash_flow (quarterly, 2025-03-31) — Purchase Of Investment: -35430000000.00
APO balance_sheet (quarterly, 2025-03-31) — Receivables: 9424000000.00
APO income_statement (quarterly, 2025-03-31) — Reconciled Cost Of Revenue: 326000000.00
APO income_statement (quarterly, 2025-03-31) — Reconciled Depreciation: 308000000.00
APO cash_flow (quarterly, 2025-03-31) — Repayment Of Debt: -818000000.00
APO cash_flow (quarterly, 2025-03-31) — Repurchase Of Capital Stock: -193000000.00
APO balance_sheet (quarterly, 2025-03-31) — Restricted Cash: 2213000000.00
APO income_statement (quarterly, 2025-03-31) — Restructuring And Mergern Acquisition: 267000000.00
APO balance_sheet (quarterly, 2025-03-31) — Retained Earnings: 5634000000.00
APO income_statement (quarterly, 2025-03-31) — Salaries And Wages: 419000000.00
APO cash_flow (quarterly, 2025-03-31) — Sale Of Business: 18976000000.00
APO income_statement (quarterly, 2025-03-31) — Selling General And Administration: 727000000.00
APO balance_sheet (quarterly, 2025-03-31) — Share Issued: 570432275.00
APO income_statement (quarterly, 2025-03-31) — Special Income Charges: -267000000.00
APO cash_flow (quarterly, 2025-03-31) — Stock Based Compensation: 149000000.00
APO balance_sheet (quarterly, 2025-03-31) — Stockholders Equity: 17976000000.00
APO balance_sheet (quarterly, 2025-03-31) — Tangible Book Value: 12247000000.00
APO income_statement (quarterly, 2025-03-31) — Tax Effect Of Unusual Items: -17922000.00
APO income_statement (quarterly, 2025-03-31) — Tax Provision: 243000000.00
APO income_statement (quarterly, 2025-03-31) — Tax Rate For Calcs: 0.21
APO balance_sheet (quarterly, 2025-03-31) — Total Assets: 395045000000.00
APO balance_sheet (quarterly, 2025-03-31) — Total Capitalization: 28557000000.00
APO balance_sheet (quarterly, 2025-03-31) — Total Debt: 10581000000.00
APO balance_sheet (quarterly, 2025-03-31) — Total Equity Gross Minority Interest: 32344000000.00
APO income_statement (quarterly, 2025-03-31) — Total Expenses: 4023000000.00
APO balance_sheet (quarterly, 2025-03-31) — Total Liabilities Net Minority Interest: 362701000000.00
APO balance_sheet (quarterly, 2025-03-31) — Total Non Current Assets: 166977000000.00
APO balance_sheet (quarterly, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 77528000000.00
APO income_statement (quarterly, 2025-03-31) — Total Unusual Items: -87000000.00
APO income_statement (quarterly, 2025-03-31) — Total Unusual Items Excluding Goodwill: -87000000.00
APO balance_sheet (quarterly, 2025-03-31) — Working Capital: -57105000000.00
APO income_statement (quarterly, 2025-06-30) — +Operating Expense: 5036000000.00
APO income_statement (quarterly, 2025-06-30) — +Total Revenue: 6814000000.00
APO balance_sheet (quarterly, 2025-06-30) — Accounts Payable: 4079000000.00
APO balance_sheet (quarterly, 2025-06-30) — Additional Paid In Capital: 15697000000.00
APO balance_sheet (quarterly, 2025-06-30) — Available For Sale Securities: 1416000000.00
APO income_statement (quarterly, 2025-06-30) — Average Dilution Earnings: 0.00
APO income_statement (quarterly, 2025-06-30) — Basic Average Shares: 586672682.00
APO income_statement (quarterly, 2025-06-30) — Basic EPS: 1.00
APO cash_flow (quarterly, 2025-06-30) — Beginning Cash Position: 15513000000.00
APO balance_sheet (quarterly, 2025-06-30) — Capital Stock: 1398000000.00
APO balance_sheet (quarterly, 2025-06-30) — Cash And Cash Equivalents: 13248000000.00
APO balance_sheet (quarterly, 2025-06-30) — Cash Cash Equivalents And Short Term Investments: 231466000000.00
APO cash_flow (quarterly, 2025-06-30) — Cash Dividends Paid: -331000000.00
APO cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Financing Activities: 17815000000.00
APO cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Investing Activities: -19629000000.00
APO cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Operating Activities: 1262000000.00
APO cash_flow (quarterly, 2025-06-30) — Change In Other Current Liabilities: -784000000.00
APO cash_flow (quarterly, 2025-06-30) — Change In Other Working Capital: 2305000000.00
APO cash_flow (quarterly, 2025-06-30) — Change In Working Capital: 1521000000.00
APO cash_flow (quarterly, 2025-06-30) — Changes In Cash: -552000000.00
APO balance_sheet (quarterly, 2025-06-30) — Common Stock: 0.00
APO cash_flow (quarterly, 2025-06-30) — Common Stock Dividend Paid: -306000000.00
APO balance_sheet (quarterly, 2025-06-30) — Common Stock Equity: 17923000000.00
APO cash_flow (quarterly, 2025-06-30) — Common Stock Payments: 0.00
APO income_statement (quarterly, 2025-06-30) — Cost Of Revenue: 330000000.00
APO balance_sheet (quarterly, 2025-06-30) — Current Assets: 243225000000.00
APO balance_sheet (quarterly, 2025-06-30) — Current Deferred Liabilities: 292238000000.00
APO balance_sheet (quarterly, 2025-06-30) — Current Deferred Revenue: 292238000000.00
APO balance_sheet (quarterly, 2025-06-30) — Current Liabilities: 304337000000.00
APO cash_flow (quarterly, 2025-06-30) — Depreciation Amortization Depletion: 332000000.00
APO cash_flow (quarterly, 2025-06-30) — Depreciation And Amortization: 332000000.00
APO income_statement (quarterly, 2025-06-30) — Diluted Average Shares: 590371367.00
APO income_statement (quarterly, 2025-06-30) — Diluted EPS: 0.99
APO income_statement (quarterly, 2025-06-30) — Diluted NI Availto Com Stockholders: 292000000.00
APO balance_sheet (quarterly, 2025-06-30) — Duefrom Related Parties Current: 763000000.00
APO balance_sheet (quarterly, 2025-06-30) — Dueto Related Parties Current: 760000000.00
APO income_statement (quarterly, 2025-06-30) — EBIT: 924000000.00
APO income_statement (quarterly, 2025-06-30) — EBITDA: 1256000000.00
APO cash_flow (quarterly, 2025-06-30) — Effect Of Exchange Rate Changes: 10000000.00
APO cash_flow (quarterly, 2025-06-30) — End Cash Position: 14971000000.00
APO balance_sheet (quarterly, 2025-06-30) — Financial Assets: 6901000000.00
APO cash_flow (quarterly, 2025-06-30) — Financing Cash Flow: 17815000000.00
APO cash_flow (quarterly, 2025-06-30) — Free Cash Flow: 1262000000.00
APO cash_flow (quarterly, 2025-06-30) — Gain Loss On Investment Securities: -663000000.00
APO income_statement (quarterly, 2025-06-30) — Gain On Sale Of Security: -250000000.00
APO balance_sheet (quarterly, 2025-06-30) — Gains Losses Not Affecting Retained Earnings: -3693000000.00
APO income_statement (quarterly, 2025-06-30) — General And Administrative Expense: 642000000.00
APO balance_sheet (quarterly, 2025-06-30) — Goodwill: 4339000000.00
APO balance_sheet (quarterly, 2025-06-30) — Goodwill And Other Intangible Assets: 4339000000.00
APO income_statement (quarterly, 2025-06-30) — Gross Profit: 6484000000.00
APO cash_flow (quarterly, 2025-06-30) — Income Tax Paid Supplemental Data: 275000000.00
APO income_statement (quarterly, 2025-06-30) — Interest Expense: 79000000.00
APO income_statement (quarterly, 2025-06-30) — Interest Expense Non Operating: 79000000.00
APO income_statement (quarterly, 2025-06-30) — Interest Income: 5000000.00
APO income_statement (quarterly, 2025-06-30) — Interest Income Non Operating: 5000000.00
APO cash_flow (quarterly, 2025-06-30) — Interest Paid Supplemental Data: 94000000.00
APO balance_sheet (quarterly, 2025-06-30) — Invested Capital: 30067000000.00
APO cash_flow (quarterly, 2025-06-30) — Investing Cash Flow: -19629000000.00
APO balance_sheet (quarterly, 2025-06-30) — Investmentin Financial Assets: 1416000000.00
APO balance_sheet (quarterly, 2025-06-30) — Investments And Advances: 138811000000.00
APO cash_flow (quarterly, 2025-06-30) — Issuance Of Debt: 2338000000.00
APO balance_sheet (quarterly, 2025-06-30) — Long Term Debt: 12144000000.00
APO balance_sheet (quarterly, 2025-06-30) — Long Term Debt And Capital Lease Obligation: 12144000000.00
APO cash_flow (quarterly, 2025-06-30) — Long Term Debt Issuance: 2338000000.00
APO cash_flow (quarterly, 2025-06-30) — Long Term Debt Payments: -467000000.00
APO balance_sheet (quarterly, 2025-06-30) — Long Term Equity Investment: 1175000000.00
APO balance_sheet (quarterly, 2025-06-30) — Minority Interest: 14540000000.00
APO income_statement (quarterly, 2025-06-30) — Minority Interests: -212000000.00
APO cash_flow (quarterly, 2025-06-30) — Net Business Purchase And Sale: 15907000000.00
APO cash_flow (quarterly, 2025-06-30) — Net Common Stock Issuance: 0.00
APO income_statement (quarterly, 2025-06-30) — Net Income: 630000000.00
APO income_statement (quarterly, 2025-06-30) — Net Income Common Stockholders: 292000000.00
APO income_statement (quarterly, 2025-06-30) — Net Income Continuous Operations: 842000000.00
APO income_statement (quarterly, 2025-06-30) — Net Income From Continuing And Discontinued Operation: 630000000.00
APO income_statement (quarterly, 2025-06-30) — Net Income From Continuing Operation Net Minority Interest: 630000000.00
APO cash_flow (quarterly, 2025-06-30) — Net Income From Continuing Operations: 842000000.00
APO income_statement (quarterly, 2025-06-30) — Net Income Including Noncontrolling Interests: 842000000.00
APO income_statement (quarterly, 2025-06-30) — Net Interest Income: -74000000.00
APO cash_flow (quarterly, 2025-06-30) — Net Investment Purchase And Sale: -34368000000.00
APO cash_flow (quarterly, 2025-06-30) — Net Issuance Payments Of Debt: 1871000000.00
APO cash_flow (quarterly, 2025-06-30) — Net Long Term Debt Issuance: 1871000000.00
APO income_statement (quarterly, 2025-06-30) — Net Non Operating Interest Income Expense: -74000000.00
APO cash_flow (quarterly, 2025-06-30) — Net Other Financing Charges: 16275000000.00
APO cash_flow (quarterly, 2025-06-30) — Net Other Investing Changes: -1168000000.00
APO balance_sheet (quarterly, 2025-06-30) — Net Tangible Assets: 14982000000.00
APO balance_sheet (quarterly, 2025-06-30) — Non Current Deferred Assets: 7981000000.00
APO income_statement (quarterly, 2025-06-30) — Normalized EBITDA: 1798000000.00
APO income_statement (quarterly, 2025-06-30) — Normalized Income: 1169832000.00
APO cash_flow (quarterly, 2025-06-30) — Operating Cash Flow: 1262000000.00
APO cash_flow (quarterly, 2025-06-30) — Operating Gains Losses: -663000000.00
APO income_statement (quarterly, 2025-06-30) — Operating Income: 1448000000.00
APO income_statement (quarterly, 2025-06-30) — Operating Revenue: 6809000000.00
APO balance_sheet (quarterly, 2025-06-30) — Ordinary Shares Number: 572024038.00
APO balance_sheet (quarterly, 2025-06-30) — Other Equity Adjustments: -3693000000.00
APO income_statement (quarterly, 2025-06-30) — Other Gand A: 370000000.00
APO income_statement (quarterly, 2025-06-30) — Other Income Expense: -529000000.00
APO balance_sheet (quarterly, 2025-06-30) — Other Investments: 136220000000.00
APO cash_flow (quarterly, 2025-06-30) — Other Non Cash Items: -936000000.00
APO balance_sheet (quarterly, 2025-06-30) — Other Non Current Assets: 18293000000.00
APO balance_sheet (quarterly, 2025-06-30) — Other Non Current Liabilities: 69208000000.00
APO income_statement (quarterly, 2025-06-30) — Other Non Operating Income Expenses: 13000000.00
APO income_statement (quarterly, 2025-06-30) — Other Operating Expenses: 4394000000.00
APO balance_sheet (quarterly, 2025-06-30) — Other Payable: 7260000000.00
APO balance_sheet (quarterly, 2025-06-30) — Other Receivables: 9273000000.00
APO balance_sheet (quarterly, 2025-06-30) — Other Short Term Investments: 218218000000.00
APO income_statement (quarterly, 2025-06-30) — Otherunder Preferred Stock Dividend: 313000000.00
APO balance_sheet (quarterly, 2025-06-30) — Payables: 12099000000.00
APO balance_sheet (quarterly, 2025-06-30) — Payables And Accrued Expenses: 12099000000.00
APO balance_sheet (quarterly, 2025-06-30) — Preferred Shares Number: 28749765.00
APO balance_sheet (quarterly, 2025-06-30) — Preferred Stock: 1398000000.00
APO cash_flow (quarterly, 2025-06-30) — Preferred Stock Dividend Paid: -25000000.00
APO income_statement (quarterly, 2025-06-30) — Preferred Stock Dividends: 25000000.00
APO balance_sheet (quarterly, 2025-06-30) — Preferred Stock Equity: 1398000000.00
APO income_statement (quarterly, 2025-06-30) — Pretax Income: 845000000.00
APO cash_flow (quarterly, 2025-06-30) — Purchase Of Business: -2977000000.00
APO cash_flow (quarterly, 2025-06-30) — Purchase Of Investment: -34368000000.00
APO balance_sheet (quarterly, 2025-06-30) — Receivables: 10036000000.00
APO income_statement (quarterly, 2025-06-30) — Reconciled Cost Of Revenue: 330000000.00
APO income_statement (quarterly, 2025-06-30) — Reconciled Depreciation: 332000000.00
APO cash_flow (quarterly, 2025-06-30) — Repayment Of Debt: -467000000.00
APO cash_flow (quarterly, 2025-06-30) — Repurchase Of Capital Stock: 0.00
APO balance_sheet (quarterly, 2025-06-30) — Restricted Cash: 1723000000.00
APO income_statement (quarterly, 2025-06-30) — Restructuring And Mergern Acquisition: 292000000.00
APO balance_sheet (quarterly, 2025-06-30) — Retained Earnings: 5919000000.00
APO income_statement (quarterly, 2025-06-30) — Salaries And Wages: 272000000.00
APO cash_flow (quarterly, 2025-06-30) — Sale Of Business: 18884000000.00
APO income_statement (quarterly, 2025-06-30) — Selling General And Administration: 642000000.00
APO balance_sheet (quarterly, 2025-06-30) — Share Issued: 572024038.00
APO income_statement (quarterly, 2025-06-30) — Special Income Charges: -292000000.00
APO cash_flow (quarterly, 2025-06-30) — Stock Based Compensation: 166000000.00
APO balance_sheet (quarterly, 2025-06-30) — Stockholders Equity: 19321000000.00
APO balance_sheet (quarterly, 2025-06-30) — Tangible Book Value: 13584000000.00
APO income_statement (quarterly, 2025-06-30) — Tax Effect Of Unusual Items: -2168000.00
APO income_statement (quarterly, 2025-06-30) — Tax Provision: 3000000.00
APO income_statement (quarterly, 2025-06-30) — Tax Rate For Calcs: 0.00
APO balance_sheet (quarterly, 2025-06-30) — Total Assets: 419550000000.00
APO balance_sheet (quarterly, 2025-06-30) — Total Capitalization: 31465000000.00
APO balance_sheet (quarterly, 2025-06-30) — Total Debt: 12144000000.00
APO balance_sheet (quarterly, 2025-06-30) — Total Equity Gross Minority Interest: 33861000000.00
APO income_statement (quarterly, 2025-06-30) — Total Expenses: 5366000000.00
APO balance_sheet (quarterly, 2025-06-30) — Total Liabilities Net Minority Interest: 385689000000.00
APO balance_sheet (quarterly, 2025-06-30) — Total Non Current Assets: 176325000000.00
APO balance_sheet (quarterly, 2025-06-30) — Total Non Current Liabilities Net Minority Interest: 81352000000.00
APO income_statement (quarterly, 2025-06-30) — Total Unusual Items: -542000000.00
APO income_statement (quarterly, 2025-06-30) — Total Unusual Items Excluding Goodwill: -542000000.00
APO balance_sheet (quarterly, 2025-06-30) — Working Capital: -61112000000.00
APO income_statement (quarterly, 2025-09-30) — +Operating Expense: 6275000000.00
APO income_statement (quarterly, 2025-09-30) — +Total Revenue: 9823000000.00
APO balance_sheet (quarterly, 2025-09-30) — Accounts Payable: 4326000000.00
APO balance_sheet (quarterly, 2025-09-30) — Additional Paid In Capital: 16925000000.00
APO balance_sheet (quarterly, 2025-09-30) — Available For Sale Securities: 1307000000.00
APO income_statement (quarterly, 2025-09-30) — Average Dilution Earnings: 24000000.00
APO income_statement (quarterly, 2025-09-30) — Basic Average Shares: 589380547.00
APO income_statement (quarterly, 2025-09-30) — Basic EPS: 2.82
APO cash_flow (quarterly, 2025-09-30) — Beginning Cash Position: 14971000000.00
APO balance_sheet (quarterly, 2025-09-30) — Capital Stock: 1398000000.00
APO balance_sheet (quarterly, 2025-09-30) — Cash And Cash Equivalents: 18415000000.00
APO balance_sheet (quarterly, 2025-09-30) — Cash Cash Equivalents And Short Term Investments: 245964000000.00
APO cash_flow (quarterly, 2025-09-30) — Cash Dividends Paid: -330000000.00
APO cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Financing Activities: 19164000000.00
APO cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Investing Activities: -13237000000.00
APO cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Operating Activities: 303000000.00
APO cash_flow (quarterly, 2025-09-30) — Change In Other Current Liabilities: -448000000.00
APO cash_flow (quarterly, 2025-09-30) — Change In Other Working Capital: 3282000000.00
APO cash_flow (quarterly, 2025-09-30) — Change In Working Capital: 2834000000.00
APO cash_flow (quarterly, 2025-09-30) — Changes In Cash: 6230000000.00
APO balance_sheet (quarterly, 2025-09-30) — Common Stock: 0.00
APO cash_flow (quarterly, 2025-09-30) — Common Stock Dividend Paid: -306000000.00
APO balance_sheet (quarterly, 2025-09-30) — Common Stock Equity: 21739000000.00
APO cash_flow (quarterly, 2025-09-30) — Common Stock Payments: -340000000.00
APO income_statement (quarterly, 2025-09-30) — Cost Of Revenue: 376000000.00
APO balance_sheet (quarterly, 2025-09-30) — Current Assets: 259590000000.00
APO balance_sheet (quarterly, 2025-09-30) — Current Deferred Liabilities: 309737000000.00
APO balance_sheet (quarterly, 2025-09-30) — Current Deferred Revenue: 309737000000.00
APO balance_sheet (quarterly, 2025-09-30) — Current Liabilities: 324298000000.00
APO cash_flow (quarterly, 2025-09-30) — Depreciation Amortization Depletion: 400000000.00
APO cash_flow (quarterly, 2025-09-30) — Depreciation And Amortization: 400000000.00
APO income_statement (quarterly, 2025-09-30) — Diluted Average Shares: 607824766.00
APO income_statement (quarterly, 2025-09-30) — Diluted EPS: 2.78
APO income_statement (quarterly, 2025-09-30) — Diluted NI Availto Com Stockholders: 1397000000.00
APO balance_sheet (quarterly, 2025-09-30) — Duefrom Related Parties Current: 892000000.00
APO balance_sheet (quarterly, 2025-09-30) — Dueto Related Parties Current: 1169000000.00
APO income_statement (quarterly, 2025-09-30) — EBIT: 2993000000.00
APO income_statement (quarterly, 2025-09-30) — EBITDA: 3393000000.00
APO cash_flow (quarterly, 2025-09-30) — Effect Of Exchange Rate Changes: 0.00
APO cash_flow (quarterly, 2025-09-30) — End Cash Position: 21201000000.00
APO balance_sheet (quarterly, 2025-09-30) — Financial Assets: 8884000000.00
APO cash_flow (quarterly, 2025-09-30) — Financing Cash Flow: 19164000000.00
APO cash_flow (quarterly, 2025-09-30) — Free Cash Flow: 303000000.00
APO cash_flow (quarterly, 2025-09-30) — Gain Loss On Investment Securities: -3146000000.00
APO income_statement (quarterly, 2025-09-30) — Gain On Sale Of Security: 108000000.00
APO balance_sheet (quarterly, 2025-09-30) — Gains Losses Not Affecting Retained Earnings: -2492000000.00
APO income_statement (quarterly, 2025-09-30) — General And Administrative Expense: 794000000.00
APO balance_sheet (quarterly, 2025-09-30) — Goodwill: 5900000000.00
APO balance_sheet (quarterly, 2025-09-30) — Goodwill And Other Intangible Assets: 5900000000.00
APO income_statement (quarterly, 2025-09-30) — Gross Profit: 9447000000.00
APO cash_flow (quarterly, 2025-09-30) — Income Tax Paid Supplemental Data: -58000000.00
APO income_statement (quarterly, 2025-09-30) — Interest Expense: 94000000.00
APO income_statement (quarterly, 2025-09-30) — Interest Expense Non Operating: 94000000.00
APO income_statement (quarterly, 2025-09-30) — Interest Income: 35000000.00
APO income_statement (quarterly, 2025-09-30) — Interest Income Non Operating: 35000000.00
APO cash_flow (quarterly, 2025-09-30) — Interest Paid Supplemental Data: 389000000.00
APO balance_sheet (quarterly, 2025-09-30) — Invested Capital: 34370000000.00
APO cash_flow (quarterly, 2025-09-30) — Investing Cash Flow: -13237000000.00
APO balance_sheet (quarterly, 2025-09-30) — Investmentin Financial Assets: 1307000000.00
APO balance_sheet (quarterly, 2025-09-30) — Investments And Advances: 147385000000.00
APO cash_flow (quarterly, 2025-09-30) — Issuance Of Debt: 2070000000.00
APO balance_sheet (quarterly, 2025-09-30) — Long Term Debt: 12631000000.00
APO balance_sheet (quarterly, 2025-09-30) — Long Term Debt And Capital Lease Obligation: 12631000000.00
APO cash_flow (quarterly, 2025-09-30) — Long Term Debt Issuance: 2070000000.00
APO cash_flow (quarterly, 2025-09-30) — Long Term Debt Payments: -914000000.00
APO balance_sheet (quarterly, 2025-09-30) — Long Term Equity Investment: 1275000000.00
APO balance_sheet (quarterly, 2025-09-30) — Minority Interest: 16660000000.00
APO income_statement (quarterly, 2025-09-30) — Minority Interests: -725000000.00
APO cash_flow (quarterly, 2025-09-30) — Net Business Purchase And Sale: 21930000000.00
APO cash_flow (quarterly, 2025-09-30) — Net Common Stock Issuance: -340000000.00
APO income_statement (quarterly, 2025-09-30) — Net Income: 1736000000.00
APO income_statement (quarterly, 2025-09-30) — Net Income Common Stockholders: 1373000000.00
APO income_statement (quarterly, 2025-09-30) — Net Income Continuous Operations: 2461000000.00
APO income_statement (quarterly, 2025-09-30) — Net Income From Continuing And Discontinued Operation: 1736000000.00
APO income_statement (quarterly, 2025-09-30) — Net Income From Continuing Operation Net Minority Interest: 1736000000.00
APO cash_flow (quarterly, 2025-09-30) — Net Income From Continuing Operations: 2461000000.00
APO income_statement (quarterly, 2025-09-30) — Net Income Including Noncontrolling Interests: 2461000000.00
APO income_statement (quarterly, 2025-09-30) — Net Interest Income: -59000000.00
APO cash_flow (quarterly, 2025-09-30) — Net Investment Purchase And Sale: -35022000000.00
APO cash_flow (quarterly, 2025-09-30) — Net Issuance Payments Of Debt: 1156000000.00
APO cash_flow (quarterly, 2025-09-30) — Net Long Term Debt Issuance: 1156000000.00
APO income_statement (quarterly, 2025-09-30) — Net Non Operating Interest Income Expense: -59000000.00
APO cash_flow (quarterly, 2025-09-30) — Net Other Financing Charges: 18678000000.00
APO cash_flow (quarterly, 2025-09-30) — Net Other Investing Changes: -145000000.00
APO balance_sheet (quarterly, 2025-09-30) — Net Tangible Assets: 17237000000.00
APO balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Assets: 8370000000.00
APO income_statement (quarterly, 2025-09-30) — Normalized EBITDA: 3640000000.00
APO income_statement (quarterly, 2025-09-30) — Normalized Income: 1945681614.35
APO cash_flow (quarterly, 2025-09-30) — Operating Cash Flow: 303000000.00
APO cash_flow (quarterly, 2025-09-30) — Operating Gains Losses: -3146000000.00
APO income_statement (quarterly, 2025-09-30) — Operating Income: 3172000000.00
APO income_statement (quarterly, 2025-09-30) — Operating Revenue: 9817000000.00
APO balance_sheet (quarterly, 2025-09-30) — Ordinary Shares Number: 580389090.00
APO balance_sheet (quarterly, 2025-09-30) — Other Equity Adjustments: -2492000000.00
APO income_statement (quarterly, 2025-09-30) — Other Gand A: 409000000.00
APO income_statement (quarterly, 2025-09-30) — Other Income Expense: -214000000.00
APO balance_sheet (quarterly, 2025-09-30) — Other Investments: 144803000000.00
APO cash_flow (quarterly, 2025-09-30) — Other Non Cash Items: -2454000000.00
APO balance_sheet (quarterly, 2025-09-30) — Other Non Current Assets: 19414000000.00
APO balance_sheet (quarterly, 2025-09-30) — Other Non Current Liabilities: 72817000000.00
APO income_statement (quarterly, 2025-09-30) — Other Non Operating Income Expenses: 33000000.00
APO income_statement (quarterly, 2025-09-30) — Other Operating Expenses: 5481000000.00
APO balance_sheet (quarterly, 2025-09-30) — Other Payable: 9066000000.00
APO balance_sheet (quarterly, 2025-09-30) — Other Receivables: 9948000000.00
APO balance_sheet (quarterly, 2025-09-30) — Other Short Term Investments: 227549000000.00
APO income_statement (quarterly, 2025-09-30) — Otherunder Preferred Stock Dividend: 339000000.00
APO balance_sheet (quarterly, 2025-09-30) — Payables: 14561000000.00
APO balance_sheet (quarterly, 2025-09-30) — Payables And Accrued Expenses: 14561000000.00
APO balance_sheet (quarterly, 2025-09-30) — Preferred Shares Number: 28749665.00
APO balance_sheet (quarterly, 2025-09-30) — Preferred Stock: 1398000000.00
APO cash_flow (quarterly, 2025-09-30) — Preferred Stock Dividend Paid: -24000000.00
APO income_statement (quarterly, 2025-09-30) — Preferred Stock Dividends: 24000000.00
APO balance_sheet (quarterly, 2025-09-30) — Preferred Stock Equity: 1398000000.00
APO income_statement (quarterly, 2025-09-30) — Pretax Income: 2899000000.00
APO cash_flow (quarterly, 2025-09-30) — Purchase Of Business: -1678000000.00
APO cash_flow (quarterly, 2025-09-30) — Purchase Of Investment: -35022000000.00
APO balance_sheet (quarterly, 2025-09-30) — Receivables: 10840000000.00
APO income_statement (quarterly, 2025-09-30) — Reconciled Cost Of Revenue: 376000000.00
APO income_statement (quarterly, 2025-09-30) — Reconciled Depreciation: 400000000.00
APO cash_flow (quarterly, 2025-09-30) — Repayment Of Debt: -914000000.00
APO cash_flow (quarterly, 2025-09-30) — Repurchase Of Capital Stock: -340000000.00
APO balance_sheet (quarterly, 2025-09-30) — Restricted Cash: 2786000000.00
APO income_statement (quarterly, 2025-09-30) — Restructuring And Mergern Acquisition: 355000000.00
APO balance_sheet (quarterly, 2025-09-30) — Retained Earnings: 7306000000.00
APO income_statement (quarterly, 2025-09-30) — Salaries And Wages: 385000000.00
APO cash_flow (quarterly, 2025-09-30) — Sale Of Business: 23608000000.00
APO income_statement (quarterly, 2025-09-30) — Selling General And Administration: 794000000.00
APO balance_sheet (quarterly, 2025-09-30) — Share Issued: 580389090.00
APO income_statement (quarterly, 2025-09-30) — Special Income Charges: -355000000.00
APO cash_flow (quarterly, 2025-09-30) — Stock Based Compensation: 208000000.00
APO balance_sheet (quarterly, 2025-09-30) — Stockholders Equity: 23137000000.00
APO balance_sheet (quarterly, 2025-09-30) — Tangible Book Value: 15839000000.00
APO income_statement (quarterly, 2025-09-30) — Tax Effect Of Unusual Items: -37318385.65
APO income_statement (quarterly, 2025-09-30) — Tax Provision: 438000000.00
APO income_statement (quarterly, 2025-09-30) — Tax Rate For Calcs: 0.15
APO balance_sheet (quarterly, 2025-09-30) — Total Assets: 449543000000.00
APO balance_sheet (quarterly, 2025-09-30) — Total Capitalization: 35768000000.00
APO balance_sheet (quarterly, 2025-09-30) — Total Debt: 12631000000.00
APO balance_sheet (quarterly, 2025-09-30) — Total Equity Gross Minority Interest: 39797000000.00
APO income_statement (quarterly, 2025-09-30) — Total Expenses: 6651000000.00
APO balance_sheet (quarterly, 2025-09-30) — Total Liabilities Net Minority Interest: 409746000000.00
APO balance_sheet (quarterly, 2025-09-30) — Total Non Current Assets: 189953000000.00
APO balance_sheet (quarterly, 2025-09-30) — Total Non Current Liabilities Net Minority Interest: 85448000000.00
APO income_statement (quarterly, 2025-09-30) — Total Unusual Items: -247000000.00
APO income_statement (quarterly, 2025-09-30) — Total Unusual Items Excluding Goodwill: -247000000.00
APO balance_sheet (quarterly, 2025-09-30) — Working Capital: -64708000000.00
APO income_statement (annual, 2025-12-31) — +Operating Expense: 22348000000.00
APO income_statement (quarterly, 2025-12-31) — +Operating Expense: 7348000000.00
APO income_statement (annual, 2025-12-31) — +Total Revenue: 32049000000.00
APO income_statement (quarterly, 2025-12-31) — +Total Revenue: 9864000000.00
APO balance_sheet (annual, 2025-12-31) — Accounts Payable: 3861000000.00
APO balance_sheet (quarterly, 2025-12-31) — Accounts Payable: 3861000000.00
APO balance_sheet (annual, 2025-12-31) — Additional Paid In Capital: 16954000000.00
APO balance_sheet (quarterly, 2025-12-31) — Additional Paid In Capital: 16954000000.00
APO balance_sheet (annual, 2025-12-31) — Available For Sale Securities: 1088000000.00